Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATNF 
180 Life Sciences Corp (ATNF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ATNF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $80
1 Year Target Price $80
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -24.15% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio - | 1Y Target Price 80 |
Price to earnings Ratio - | 1Y Target Price 80 | ||
Volume (30-day avg) 1 | Beta 0.41 | 52 Weeks Range 0.66 - 17.40 | Updated Date 10/17/2025 |
52 Weeks Range 0.66 - 17.40 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -14.95 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -55.46% | Return on Equity (TTM) -371.02% |
Valuation
Trailing PE - | Forward PE 6.08 | Enterprise Value 412448508 | Price to Sales(TTM) - |
Enterprise Value 412448508 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.46 | Shares Outstanding 153032000 | Shares Floating 5040504 |
Shares Outstanding 153032000 | Shares Floating 5040504 | ||
Percent Insiders 9.99 | Percent Institutions 0.06 |
Upturn AI SWOT
180 Life Sciences Corp
Company Overview
History and Background
180 Life Sciences Corp. was formed in 2020 via a merger of CannBioRx, Inc. and KBL Merger Corp. IV. The company focuses on developing novel drugs for inflammatory diseases.
Core Business Areas
- Anti-TNF Fibrosis: Developing drugs to treat fibrosis and inflammation by targeting TNF (tumor necrosis factor).
- Synthetic Cannabidiol (CBD): Researching and developing synthetic CBD-based therapies for various inflammatory conditions.
- Early-Stage Development: Focusing on early stage clinical trials for Dupuytren's contracture, early Parkinson's disease, and post-operative cognitive dysfunction.
Leadership and Structure
Dr. James Woody is the CEO. The company has a scientific advisory board consisting of experts in immunology and inflammation.
Top Products and Market Share
Key Offerings
- Anti-TNF program: Focuses on developing a novel TNF inhibitor. Market share is currently 0% as it's in development. Competitors include established TNF-alpha inhibitors like Humira (ABBV) and Remicade (JNJ).
- Synthetic Cannabidiol (CBD) program: Developing synthetic CBD analogs for unmet medical needs. Market share is also 0% as still in development. Competitors include GW Pharmaceuticals (now Jazz Pharmaceuticals) with Epidiolex (JAZZ).
- Dupuytren's Contracture: Clinical trials are ongoing. The total addressable market is large. Competitors include Xiaflex (ENDO).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, driven by innovation and regulatory approvals. The market for inflammatory disease treatments is substantial and growing.
Positioning
180 Life Sciences is a clinical-stage biotech company aiming to address unmet needs in inflammatory diseases. Its competitive advantage lies in its novel approach to TNF inhibition and synthetic CBD development.
Total Addressable Market (TAM)
The market for inflammatory disease treatments is valued in the tens of billions of dollars. 180 Life Sciences Corp is positioned to capture a share of this TAM through successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Experienced leadership team
- Focus on unmet medical needs
- Strong intellectual property portfolio (patents)
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- High risk of drug development
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
- Increasing prevalence of inflammatory diseases
Threats
- Regulatory hurdles
- Competition from established players
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- JAZZ
- ENDO
Competitive Landscape
180 Life Sciences faces significant competition from established pharmaceutical companies with greater resources and approved products. Its success depends on demonstrating the efficacy and safety of its novel therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth is driven by clinical trial progress and partnerships.
Future Projections: Future growth is highly dependent on the success of clinical trials. Analyst estimates are not readily available and would be speculative.
Recent Initiatives: Focus on clinical trials for Dupuytren's contracture, early Parkinson's disease, and post-operative cognitive dysfunction
Summary
180 Life Sciences Corp. is a high-risk, high-reward clinical-stage biotech company. Its success hinges on positive clinical trial outcomes. The company shows promise, but faces considerable regulatory and financial hurdles, requiring strong capital management and strategic partnerships to navigate the competitive biotech landscape effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 180 Life Sciences Corp
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2017-06-27 | CEO & Director Mr. Lloyd Blair Jordan L.L.B., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://180lifesciences.com |
Full time employees - | Website https://180lifesciences.com | ||
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.